Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | DRD4 | P21917 | 6/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078322 | 1.00 | MCHR1 (0.52) | MCHR1DRD2DRD4DRD3SCN4A | |
| SCHEMBL16477536 | 1.00 | MCHR1 (0.52) | MCHR1DRD2DRD4DRD3SCN4A | |
| SCHEMBL2223723 | 1.00 | MCHR1 (0.52) | MCHR1DRD2DRD4DRD3SCN4A | |
| SCHEMBL22521797 | 1.00 | MCHR1 (0.52) | MCHR1DRD2DRD4DRD3SCN4A | |
| Hydrochloric Acid SCHEMBL1847619 | 0.99 | MCHR1 (0.51) | MCHR1DRD2DRD4DRD3SCN4A | |
| SCHEMBL29631582 | 0.89 | MCHR1 (0.46) | MCHR1DRD2DRD4DRD3SCN4A | |
| SCHEMBL565485 | 0.89 | KMT2A (0.55) | MCHR1DRD2DRD4DRD3SCN4A | |
| SCHEMBL1470555 | 0.89 | KMT2A (0.55) | MCHR1DRD2DRD4DRD3SCN4A | |
| SCHEMBL556530 | 0.89 | KMT2A (0.55) | MCHR1DRD2DRD4DRD3SCN4A | |
| SCHEMBL15765888 | 0.89 | KMT2A (0.55) | MCHR1DRD2DRD4DRD3SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421455-B1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2019-03-27 | — | — | EP | disclosed |
| EP-3421455-B1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2019-03-27 | — | — | EP | disclosed |
| US-20190002407-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2019-01-03 | — | — | US | disclosed |
| US-20190002407-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2019-01-03 | — | — | US | disclosed |
| EP-3421455-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-01-02 | — | — | EP | disclosed |
| EP-3421455-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-01-02 | — | — | EP | disclosed |
| US-7084277-B2 | Reacting 1-alkoxycarbonyl-3-oxo piperidine compound with an amine; reducing with reducing agent | PFIZER INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1572649-A2 | 3-AMINO-PIPERIDINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004046112-A2 | 3-AMINO-PIPERIDINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | PFIZER PRODUCTS INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040102627-A1 | 3-Amino-piperadine derivatives and methods of manufacture | PFIZER INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102627-A1 | 3-Amino-piperadine derivatives and methods of manufacture | PRMT5, SRM, CYP1B1 | MCHR1 1780/4885DRD2 109/4885DRD4 79/4885 |
| US-20190002407-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-AMINO-PIPERIDINS, USEFUL INTERMEDIATES FOR THE PREPARATION OF TOFACITINIB | JAK3, JAK2, JAK1 | MCHR1 2617/4885DRD2 938/4885DRD4 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.